Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
| ▸ | RYR2 | Q92736 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | IAPP | P10997 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569811 | 0.88 | AKR1B1 (0.36) | LMNAMAPTALDH1A1AKR1B1RYR2 | |
| SCHEMBL25569782 | 0.84 | AKR1B1 (0.36) | LMNAMAPTALDH1A1SLC5A2AKR1B1 | |
| SCHEMBL1861656 | 0.83 | AKR1B1 (0.50) | LMNAMAPTALDH1A1AKR1B1 | |
| SCHEMBL1863391 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1RYR2SLC6A4 | |
| SCHEMBL14172986 | 0.79 | CTSL (0.46) | LMNAMAPTALDH1A1SLC5A2RYR2 | |
| SCHEMBL5757690 | 0.75 | SLC5A2 (0.42) | LMNAMAPTALDH1A1SLC5A2CTSL | |
| SCHEMBL10687927 | 0.75 | ATM (0.44) | LMNAMAPTALDH1A1 | |
| SCHEMBL27765592 | 0.75 | CYP3A4 (0.49) | LMNAMAPTALDH1A1SLC5A2RYR2 | |
| SCHEMBL9838345 | 0.74 | AKR1B1 (0.48) | LMNAMAPTALDH1A1SLC5A2AKR1B1 | |
| SCHEMBL25569805 | 0.72 | AKR1B1 (0.38) | LMNAMAPTALDH1A1AKR1B1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | LMNA 4660/4885MAPT 63/4885ALDH1A1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.